Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors

Histone deacetylase inhibitors (HDIs) are a new class of drugs with significant antileukemic activity. To explore mechanisms of disease-specific HDI activity in acute myeloid leukaemia (AML), we have characterised expression of all 18 members of the histone deacetylase family in primary AML blasts and in four control cell types, namely CD34+ progenitors from umbilical cord, either quiescent or cycling (post-culture), cycling CD34+ progenitors from GCSF-stimulated adult donors and peripheral blood mononuclear cells. Only SIRT1 was consistently overexpressed (>2 fold) in AML samples compared with all controls, while HDAC6 was overexpressed relative to adult, but not neo-natal cells. HDAC5 and SIRT4 were consistently underexpressed. AML blasts and cell lines, exposed to HDIs in culture, showed both histone hyperacetylation and, unexpectedly, specific hypermethylation of H3 lysine 4. Such treatment also modulated the pattern of HDAC expression, with strong induction of HDAC11 in all myeloid cells tested and with all inhibitors (valproate, butyrate, TSA, SAHA), and lesser, more selective, induction of HDAC9 and SIRT4. The distinct pattern of HDAC expression in AML and its response to HDIs is of relevance to the development of HDI-based therapeutic strategies and may contribute to observed patterns of clinical response and development of drug resistance.

[1]  H. Schulman,et al.  Acetylation and calcium-dependent phosphorylation of histone H3 in nuclei from butyrate-treated HeLa cells. , 1983, The Journal of biological chemistry.

[2]  B. Turner,et al.  Histone H4 acetylation in human cells Frequency of acetylation at different sites defined by immunolabeling with site‐specific antibodies , 1989, FEBS letters.

[3]  B. Turner,et al.  Histone H4 acetylation in Drosophila Frequency of acetylation at different sites defined by immunolabelling with site‐specific antibodies , 1991, FEBS letters.

[4]  H. Drexler,et al.  Leukemia cell lines: in vitro models for the study of acute promyelocytic leukemia. , 1995, Leukemia research.

[5]  C. Van Lint,et al.  The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. , 1996, Gene expression.

[6]  D. A. White,et al.  Preparation of site-specific antibodies to acetylated histones. , 1999, Methods.

[7]  Ping Zhu,et al.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.

[8]  Delin Chen,et al.  Negative Control of p53 by Sir2α Promotes Cell Survival under Stress , 2001, Cell.

[9]  P. Pelicci,et al.  Effects of the acute myeloid leukemia--associated fusion proteins on nuclear architecture. , 2001, Seminars in hematology.

[10]  B. Turner,et al.  dSIR2 and dHDAC6: two novel, inhibitor-resistant deacetylases in Drosophila melanogaster. , 2001, Experimental cell research.

[11]  R. Weinberg,et al.  hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase , 2001, Cell.

[12]  Colin A. Johnson,et al.  Human Class I Histone Deacetylase Complexes Show Enhanced Catalytic Activity in the Presence of ATP and Co-immunoprecipitate with the ATP-dependent Chaperone Protein Hsp70* , 2002, The Journal of Biological Chemistry.

[13]  S. Horinouchi,et al.  In vivo destabilization of dynamic microtubules by HDAC6‐mediated deacetylation , 2002, The EMBO journal.

[14]  P. Marks,et al.  Histone deacetylase inhibitors: from target to clinical trials , 2002, Expert opinion on investigational drugs.

[15]  Matty P. Weijenberg,et al.  A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer , 2002, Nature Genetics.

[16]  Fred Asselbergs,et al.  Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family* , 2002, The Journal of Biological Chemistry.

[17]  Thomas A Milne,et al.  MLL targets SET domain methyltransferase activity to Hox gene promoters. , 2002, Molecular cell.

[18]  J. Licht,et al.  Histone deacetylases as therapeutic targets in hematologic malignancies. , 2002, Current opinion in hematology.

[19]  S. Minucci,et al.  Human SIR2 deacetylates p53 and antagonizes PML/p53‐induced cellular senescence , 2002, The EMBO journal.

[20]  Ping Zhu,et al.  The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2 , 2003, The EMBO journal.

[21]  S. Kyrylenko,et al.  Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases , 2003, Cellular and Molecular Life Sciences CMLS.

[22]  F. Alt,et al.  Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Pandolfi,et al.  Targeting aberrant transcriptional repression in acute myeloid leukemia. , 2003, Reviews in clinical and experimental hematology.

[24]  Po Zhao,et al.  Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state. , 2003, Molecular cell.

[25]  A. V. van Kuilenburg,et al.  Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.

[26]  T. Jenuwein,et al.  An epigenetic road map for histone lysine methylation , 2003, Journal of Cell Science.

[27]  Steven P. Gygi,et al.  Stress-Dependent Regulation of FOXO Transcription Factors by the SIRT1 Deacetylase , 2004, Science.

[28]  P. Marks,et al.  Histone deacetylase inhibitors. , 2004, Advances in cancer research.

[29]  Delin Chen,et al.  Mammalian SIRT1 Represses Forkhead Transcription Factors , 2004, Cell.

[30]  J. Milbrandt,et al.  Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration , 2004, Science.

[31]  E. Seto,et al.  Regulation of histone deacetylase activities , 2004, Journal of cellular biochemistry.

[32]  L. Guarente,et al.  The Sir2 family of protein deacetylases. , 2004, Annual review of biochemistry.

[33]  Ivan V. Gregoretti,et al.  Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. , 2004, Journal of molecular biology.

[34]  Ping Zhu,et al.  Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. , 2004, Cancer cell.

[35]  Myriam Gorospe,et al.  Calorie Restriction Promotes Mammalian Cell Survival by Inducing the SIRT1 Deacetylase , 2004, Science.

[36]  Y. Yatabe,et al.  Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients , 2004, International journal of cancer.

[37]  Gordon K Smyth,et al.  Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.